May 18, 2021 / 01:10PM GMT
Daniel James Busby - RBC Capital Markets, Research Division - Assistant VP
I'm Dan Busby, the pharmaceuticals analyst at RBC Capital Markets. Our next company presenting this morning is Viatris, which was created not too long ago by the combination of Mylan and Pfizer's former Upjohn business.
I'm joined this morning by Viatris' Chief Executive Officer, Michael Goettler; as well as the company's Chief Financial Officer, Sanjeev Narula.
Michael, before we jump into Q&A, why don't I turn it over to you for a minute or 2 just to provide some brief background on Viatris and the rationale for last year's deal for those investors who may not be as familiar with the story.
Michael Goettler - Viatris Inc. - CEO & Executive Director
Sure. Dan, thank you very much, and thanks for having us today. And I would say this conference really comes at a great time for us. As you know, as you just said, Viatris as a combined company, is still a relatively new company, formed a little bit less than 6 months ago, in November. And the vision we had was to
Viatris Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers